remarkable improvement in survival through early detection and curative surgery, there were approximately 50 000 deaths from gastric cancer in 1997. Unresectable advanced or recurrent gastric cancer still shows a poor prognosis.
The objective of this retrospective study was to clarify the efficacy and safety of CPT-11 and CDDP cisplatin therapy in patients with prior chemotherapy for advanced or recurrent gastric cancer.
Patients and methods

Recruitment criteria
The subjects were 32 patients who were treated with CPT-11 and CDDP between September 2002 and September 2004 at the Shizuoka Cancer Center, Shizuoka, Japan. Patients who were recruited into the study fulfilled the following inclusion criteria: (1) histologically proven gastric cancer with metastatic lesions; (2) Eastern Clinical Oncology Group performance status of 2 or less; (3) age of 75 years or younger; (4) at least one prior chemotherapy regimen without CPT-11 or CDDP; (5) adequate bone marrow (WBC count ≥ 4000/ µl and platelet count ≥ 10 000/µl), liver (serum bilirubin level ≤ 1.5 mg/dl and serum transaminase level ≤ three times the upper limit of normal range), and renal function (serum creatinine level ≤ 1.5 mg/dl, blood urea nitrogen level ≤ 25 mg/dl); (6) normal cardiac function; (7) no other severe medical conditions; (8) no other active malignancy; and (9) the provision of written informed consent.
Statement of patients' informed consent
Patients and their families submitted written informed consent prior to entry into the study. The information supplied covered: (1) the name of the disease and condition; (2) method and contents of the treatment; (3) expected response and side effects; (4) other possible outcomes; (5) advantages and disadvantages; (6) agreement, denial, and retraction; and, (7) human rights protection.
Treatment schedule
CPT-11 (70 mg/m 2 ) was administered by intravenous infusion for 90 min on day 1; this was followed by a 2-h interval, after which an intravenous infusion of CDDP (80 mg/m 2 ) was administered over 2 h, with adequate hydration. The same dose of CPT-11 was administered on day 15. This treatment was repeated every 4 weeks until disease progression, patient refusal, or unacceptable adverse reactions. On day 15, if the patient had a WBC count of 2800/µl or less or 12 000/µl or more, a platelet count of 100 000/µl or less, diarrhea of grade 1 or higher, or an episode of infection, then CPT-11 on day 15 was postponed until recovery from these adverse reactions. If these adverse reactions continued beyond day 22, then the CPT-11 which should have been administered on day 15 was skipped. If a hematological adverse reaction was grade 4, or a nonhematological adverse reaction was grade 3 or higher, then CPT-11 on day 15 was skipped, and the subsequent dose of CPT-11 was reduced to 60 mg/m 2 . Granisetron was used routinely before the administration of CPT-11. Granulocyte colony-stimulating factor (G-CSF) was used when necessary.
Evaluation
Tumor measurements for response assessment were obtained every 1-2 months by computed tomography (CT). The objective response to chemotherapy in measurable lesions was evaluated by the Response Evaluation Criteria in Solid Tumors [12] . National Cancer Institute common toxicity criteria (NCI-CTC; version 2) were adopted to evaluate the adverse reactions. The survival time was calculated from the day of the initiation of treatment to the date of death or the last date of confirmation of alive (censored), by the Kaplan-Meier method.
Patient characteristics
Patient characteristics are listed in Table 1 . The median age of all patients was 58 years (range, 37-75 years). with metastases in lymph nodes, 4 (13%) with metastases in lung, 13 (41%) with peritoneal dissemination, and 9 (28%) with ascites. Prior chemotherapy regimens are listed in Table 1 , and all patients showed progressive disease before the initiation of the regimen used in the present study.
Results
Response and survival
Twenty-eight patients with measurable metastatic lesions were assessable for clinical response. There were eight partial responses, resulting in an overall response rate of 28% (Table 2) . Median time to progression was 104 days (range, 24-863 days) and median overall survival time was 283 days, with a median follow-up time of 345 days (Figs. 1, 2) .
Adverse reactions
The total number of treatment courses was 109, and the median number in each patient was 2.5 courses (range, 1-6 courses). The adverse reactions to this regimen are summarized in Table 3 . The most frequent reaction was neutropenia, with grade 4 neutropenia observed in 22 patients (69%), and grade 3 or higher infection observed in only 3 patients (9%). Other hematologic adverse reactions were mild. Grade 3 diarrhea was observed in 1 patient (3%). Other grade 3 or 4 
Dose intensity
The planned administration of CPT-11 on day 15 was not given 27 (25%) times in 15 patients (47%) during the 109 courses. Dose reduction of CPT-11 was required in 7 (22%) patients. Leukopenia was the most common reason for skipping the administration of CPT-11 on day 15 and for the dose reduction of CPT-11 (days 1 and 15). Thus, the dose intensity of CPT-11 was 24.5 mg/m 2 per week and that of CDDP was 15.4 mg/m 2 per week, which corresponded to 70% and 77% of the planned doses, respectively.
Further chemotherapy
Twenty-six patients (81%) received further chemotherapy after failure of the CPT-11 + CDDP regimen ( Table 4 ). The condition of the remaining 6 patients made them unsuitable to receive third-line chemotherapy.
Discussion
Because the administration of CPT-11 is contraindicated for patients with myelosupression, infection, diarrhea, ileus, interstitial pneumonia, and obstructive jaundice, for fear of its severe toxicity, in clinical practice we selected patients with good PS and mild peritoneal dissemination for second-line chemotherapy with CPT-11. Of all the patients, 30 (94%) had a PS of 0 or 1, 13 (41%) had peritoneal dissemination, and 9 (28%) had ascites; however, none had massive ascites. Thus, this study contained a certain level of selection bias.
In our study, the actual dose intensity of CPT-11 was 70% of the planned dose, which was lower than that in a previous report (81.4% [10] ). Leukopenia was the most common reason for skipping the administration of CPT-11 on day 15, and for the dose reduction of CPT-11. The incidences of grade 4 neutropenia (69%) and grade 3 or 4 infection (9%) were higher than those in the previous report [10] , showing 57% and 5%, respectively. The high incidence of neutropenia in our study may have been caused by the prior chemotherapy. On the other hand, the incidence of grade 3 or 4 diarrhea (3%) was lower than that in the previous report (20% [10] ), and other toxicities were mild, with frequencies similar to those in the previous report. Although dose reduction was required in some of our selected patients, this regimen is considered to be feasible for patients with prior chemotherapy.
CPT-11 has activity against gastric carcinoma. When used as a single agent for untreated and treated gastric cancer patients, Kambe et al. [13] reported a response rate of 23%. A recent European study of single-agent CPT-11 therapy reported a response rate of 17% in 34 previously untreated patients with gastric cancer [14] . There are a few reports of CPT-11 used in second-line combination chemotherapy regimens. Boku et al. [10] reported that CPT-11 and CDDP showed a response rate of 27%. In a report by Ajani et al. [15] , this combination showed a response rate of 31%, with a median survival of 150 days. In a phase II study of CPT-11 and mitomycin C (MMC) [16] , the response rate was 29%, and the median survival was 306 days. Kim et al. [17] reported that CPT-11, 5-FU, and leucovorin showed a response rate of 21%, and the median survival was 273 days. From the results of these studies, it seems that combination chemotherapy with CPT-11 may have a slightly higher response rate in second-line chemotherapy for gastric cancer than CPT-11 alone.
Both paclitaxel and docetaxel have been widely used in second-line chemotherapy for gastric cancer. Arai et al. [18] reported that the response rate to paclitaxel was 23%, and the median survival was 207 days. Park et al. [19] reported that combination chemotherapy with docetaxel and CCDP showed a response rate of 17%, with a median survival of 174 days. These results seem to be comparable with those of CPT-11-containing chemotherapy as a second-line chemotherapeutic regimen for gastric cancer.
In conclusion, the combination of CPT-11 and CDDP may be active and feasible for patients with prior chemotherapy for gastric cancer. To establish standard second-line chemotherapy for gastric cancer, especially after the failure of a 5-FU-based regimen, a CPT-11-based regimen and a taxane-based regimen should be compared in a randomized study. 
